This content is in French.
Low-dose aspirin in hepatic steatosis
22 mars 2024
Aspirin has been shown to have an effect on the progression of hepatic steatosis to end-stage liver disease and hepatocellular carcinoma. But what is its effect on hepatic steatosis? In this randomized, double-blind…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Tracey G Simon et al. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial. JAMA. 2024 Mar 19;331(11):920-929.
View the sourceOther recent articles
Advanced hepatocellular carcinoma in Europe: a rapidly evolving treatment landscape
27 octobre 2026
Hepatocellular carcinoma in Europe: a shifting epidemiological landscape
27 octobre 2026
Neuromodulation for Neuropathic Pain: Which Techniques Offer the Greatest Relief?
23 octobre 2026